分子病理學與組織化學服務市場：策略性洞察與預測（2026-2035 年）

預計分子病理服務市場將從 2026 年的 178.2 億美元成長到 2035 年的 399.1 億美元，複合年成長率為 9.4%。

分子病理檢測服務市場正經歷一場根本性的變革，其驅動力是精準醫療和生物標記主導醫療的模式轉移。這一市場演變的特點是，人們日益認知到分子層面的洞察對於多個治療領域的精準診斷、治療方案選擇和疾病監測至關重要。先進的定序技術、計算生物學、檢查室自動化和生物標記發現計畫的融合，使得疾病的分子特徵分析更加全面。由於標靶治療需要在開始治療前進行生物標記確認，醫療系統正日益將分子檢測整合到常規臨床工作流程中。癌症、罕見遺傳疾病和複雜疾病的盛行率不斷上升，持續推動著對能夠提供臨床應用分子資訊的專業檢測服務的需求。生物標記主導的藥物研發正促使製藥公司拓展伴隨診斷合作，以改善患者分層和臨床試驗結果。監管機構正在加強檢查室自建檢測、伴隨診斷和基因組資料管理的標準，從而提升可靠性和臨床信心。隨著對次世代定序平台、液態生物檢體技術和人工智慧分析工具的大量投資，分子病理學和組織生理學服務已成為現代醫療保健服務的重要基礎。

市場促進因素

精準腫瘤學的擴展是分子組織病理學服務市場的主要驅動力。由於精準腫瘤學依賴於基於生物標記的治療決策，並且腫瘤學家在選擇標靶治療之前需要全面的基因組信息，因此對分子組織病理學服務的需求不斷成長。這項要求增加了檢測的複雜性，並擴大了先進分子組織病理學服務的應用。實驗室正在擴展其定序能力，以適應更廣泛的生物標記組合，從而進一步將分子檢測融入常規腫瘤學實踐中。伴隨診斷的成長進一步加速了市場擴張。伴隨診斷將治療選擇與分子層面的證據聯繫起來，隨著​​製藥公司尋求生物標記特異性藥物開發策略，對伴隨診斷的需求也在不斷成長。這種方法增加了從臨床開發到商業化各個階段對檢驗的分子檢測服務的需求。實驗室正在加強與製藥公司的合作以滿足這些需求，從而進一步整合診斷和治療。複雜疾病的日益普遍也是推動分子檢測需求成長的原因之一。複雜疾病通常涉及異質性分子機制，而傳統的診斷方法往往缺乏足夠的生物學解析度。醫療機構正在採用分子檢測來提高診斷的準確性和治療方案的精準性。實驗室服務機構正在擴大服務範圍，涵蓋更廣泛的疾病類別，推動檢測數量的持續成長。定序技術的進步提高了分析性能和可及性。臨床醫生只需一次檢測即可獲得更全面的分子訊息，而實驗室也在採用更有效率的平台來提高檢測通量並縮短結果出具時間。這些投入正在提升擴充性，並推動其在臨床實踐中的更廣泛應用。

市場限制因素

定序平台、生物資訊基礎設施和專業人員所需的大量資金阻礙了資源匱乏的醫療體系的擴張。先進設備和專業知識所需的高額初始投資是發展中地區小規模實驗室和機構的一大障礙。各國報銷方案的差異為實驗室帶來不確定性，並延緩了其在臨床環境中的廣泛應用。不同醫療體系的保險覆蓋政策限制了病患獲得先進檢測服務的機會，並為服務提供者帶來財務不確定性。複雜的監管要求增加了合規成本，並延長了新檢測服務的檢驗週期。為了跟上檢查室自建檢測（LDT）和伴隨診斷不斷變化的監管環境，必須持續進行調整，這增加了營運成本和上市時間。分子組織病理學和生物資訊學專業人員的短缺限制了檢測服務的擴充性。能夠解讀複雜基因組數據的訓練有素的人員數量有限，降低了先進分子檢測在許多醫療機構中的臨床效用。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 全球分子病理學和組織生理學服務市場：概述、市場規模和預測

• 市場定義和範圍
• 分子病理學和組織化學服務產業概覽
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測分析
• 疾病負擔和精準醫療的現狀
• 測試數量分析
• 按主要疾病領域分析患者數量
• 生物標記檢測應用趨勢
• 腫瘤分子診斷的現狀
• 伴隨診斷活用狀況分析

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 分子病理學和組織檢查服務領域的新興技術
• 產品和服務創新
• 臨床試驗分析
• 分子診斷檢測流程分析
• 技術藍圖
• 將人工智慧整合到分子病理學和組織檢查服務的工作流程中
• 數位病理學與資訊學的融合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章 全球分子病理學與組織化學服務市場：展望分析

• 分析：按技術平台
• 分析：依生物標記類型
• 分析：依樣本類型
• 分析：透過臨床應用
• 分析：透過調查方法

第9章 全球分子病理學與組織化學服務市場：細分市場分析

• 按服務類型
  • 分子診斷檢測服務
  • 伴隨診斷測試服務
  • 基因組分析服務
  • 生物標記檢測服務
  • 感染疾病分子檢測服務
  • 藥物基因體學學檢測服務
• 透過技術
  • 聚合酵素鏈鎖反應（PCR）
  • 定量PCR（qPCR）
  • 數位PCR（dPCR）
  • 次世代定序（NGS）
  • 螢光原位雜合反應（FISH）
  • 基於微陣列的偵測
  • 桑格定序
  • 其他分子技術
• 透過使用
  • 腫瘤學
  • 血液疾病
  • 感染疾病
  • 遺傳性疾病和罕見疾病
  • 神經病變
  • 心血管疾病
  • 其他用途
• 依樣本類型
  • 組織樣本
  • 血液檢體
  • 骨髓檢體
  • 細胞學檢體
  • 其他檢體類型
• 最終用戶
  • 醫院
  • 獨立診斷實驗室
  • 學術研究機構
  • 專科診所
  • 製藥和生物技術公司

第10章 全球分子病理學與組織化學服務市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章 全球分子病理學與組織化學服務市場：國家分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 印度
• 韓國
• 澳洲
• 巴西
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• Quest Diagnostics
• Labcorp
• NeoGenomics Laboratories
• Sonic Healthcare
• Eurofins Scientific
• ARUP Laboratories
• Mayo Clinic Laboratories
• Tempus AI
• Foundation Medicine
• Caris Life Sciences
• Guardant Health
• Exact Sciences
• Natera
• Fulgent Genetics
• Unilabs

第14章 全球分子病理學與組織化學服務市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Molecular Pathology Market is anticipated to grow at a CAGR of 9.4% from USD 17.82 billion in 2026 to USD 39.91 billion in 2035.

The molecular pathology services market is experiencing fundamental transformation driven by the paradigm shift toward precision medicine and biomarker-driven healthcare. The market's evolution is characterized by the growing recognition that molecular insights are essential for accurate diagnosis, treatment selection, and disease monitoring across multiple therapeutic areas. The convergence of advanced sequencing technologies, computational biology, laboratory automation, and biomarker discovery programs is enabling more comprehensive molecular characterization of diseases. Healthcare systems are increasingly integrating molecular testing into routine clinical workflows because targeted therapies require biomarker confirmation before treatment initiation. The rising prevalence of cancer, rare genetic disorders, and complex diseases is creating sustained demand for specialized testing services capable of generating clinically actionable molecular insights. Pharmaceutical companies are expanding companion diagnostic collaborations because biomarker-driven drug development improves patient stratification and clinical trial outcomes. Regulatory agencies are strengthening standards surrounding laboratory-developed tests, companion diagnostics, and genomic data management, supporting reliability and clinical confidence. The market is witnessing significant investment in next-generation sequencing platforms, liquid biopsy technologies, and AI-enabled interpretation tools, positioning molecular pathology services as a critical enabler of modern healthcare delivery.

Market Drivers

The expansion of precision oncology represents the primary driver for the molecular pathology services market. Precision oncology relies on biomarker-guided treatment decisions, and demand is increasing because oncologists require comprehensive genomic insights before selecting targeted therapies. This requirement raises testing complexity and expands the use of advanced molecular pathology services. Laboratories are expanding sequencing capabilities to accommodate broader biomarker panels, resulting in stronger integration of molecular testing within routine oncology care. The growth of companion diagnostics is further accelerating market expansion. Companion diagnostics link therapeutic selection with molecular evidence, and demand is increasing because pharmaceutical developers are pursuing biomarker-specific drug development strategies. This approach increases the need for validated molecular testing services across clinical development and commercialization stages. Laboratories are strengthening partnerships with drug developers to support these requirements, resulting in greater alignment between diagnostics and therapeutics. The rising prevalence of complex diseases is driving demand for molecular testing. Complex diseases often involve heterogeneous molecular mechanisms, and traditional diagnostic methods frequently provide insufficient biological resolution. Healthcare providers are adopting molecular testing to improve diagnostic confidence and treatment planning. Laboratories are expanding service portfolios to address broader disease categories, resulting in sustained growth in testing volumes. Advances in sequencing technologies are improving analytical performance and accessibility. Clinicians can obtain broader molecular information from a single test, and laboratories are adopting more efficient platforms to improve throughput and reduce turnaround times. These investments enhance scalability and support wider clinical adoption.

Market Restraints

High capital requirements for sequencing platforms, bioinformatics infrastructure, and specialized personnel limit expansion in resource-constrained healthcare systems. The significant upfront investment needed for sophisticated equipment and expertise creates barriers for smaller laboratories and facilities in developing regions. Reimbursement variability across countries creates uncertainty for laboratories and delays broader clinical adoption. Inconsistent coverage policies across different healthcare systems limit patient access to advanced testing options and create financial uncertainty for service providers. Complex regulatory requirements increase compliance costs and extend validation timelines for new testing services. The evolving regulatory landscape for laboratory-developed tests and companion diagnostics requires continuous adaptation, increasing operational costs and time-to-market. Shortages of specialized molecular pathology and bioinformatics expertise constrain the scalability of testing services. The limited availability of trained personnel capable of interpreting complex genomic data reduces the clinical utility of advanced molecular testing in many healthcare settings.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of high-content molecular testing platforms. Demand is increasing for NGS because clinicians require broader molecular insights from a single analysis. PCR-based technologies remain widely utilized because they offer reliable and cost-effective molecular detection. Digital PCR adoption is increasing because clinicians require highly sensitive biomarker quantification. FISH technologies remain important for chromosomal and gene rearrangement assessments. Microarray-based testing supports specialized applications where large-scale genomic screening is required. Laboratories are investing in advanced sequencing technologies because healthcare providers seek comprehensive molecular characterization. The segment analysis reveals that molecular diagnostic testing services represent the foundational segment because healthcare providers require molecular evidence for diagnosis and disease classification. Companion diagnostic testing demand is increasing because targeted therapies often depend on biomarker confirmation. Genomic profiling services are expanding because comprehensive molecular characterization supports precision oncology programs. Biomarker testing services continue gaining importance as treatment pathways become increasingly personalized. Oncology dominates molecular pathology service utilization because biomarker-driven therapies require extensive molecular characterization. Demand is increasing in hematological disorders because genetic profiling supports diagnosis and treatment planning. Infectious disease applications continue evolving as molecular testing improves pathogen identification. Genetic and rare disease diagnostics are expanding because sequencing technologies improve diagnostic yield. Hospitals and independent diagnostic laboratories represent key end-user segments, with pharmaceutical and biotechnology companies playing an increasingly important role in companion diagnostic development. The integration of artificial intelligence is becoming increasingly important because molecular datasets continue growing in complexity. AI-enabled interpretation tools are improving clinical reporting efficiency and variant classification, supporting scalable precision medicine implementation.

Competitive and Strategic Outlook

The competitive landscape features large national laboratory networks alongside specialized oncology-focused and data-driven precision medicine providers. Quest Diagnostics distinguishes itself through its extensive laboratory network, broad testing portfolio, and strong payer relationships, continuing to expand advanced molecular testing services while leveraging national infrastructure. Labcorp differentiates itself through integrated laboratory services, clinical trial support capabilities, and broad diagnostic expertise, with strong positioning across both clinical diagnostics and drug development services. NeoGenomics specializes in oncology-focused testing services, with strong positioning within precision oncology markets through emphasis on cancer diagnostics, genomic profiling, and pharmaceutical partnerships. Sonic Healthcare leverages a global laboratory footprint and diversified diagnostic operations, continuing to expand molecular testing capabilities while supporting precision medicine initiatives across multiple regions. Eurofins Scientific benefits from extensive laboratory infrastructure and broad scientific expertise, supporting clinical diagnostics, pharmaceutical services, and specialized molecular testing programs. ARUP Laboratories maintains strong academic affiliations and advanced testing capabilities, with differentiation within complex molecular testing applications. Mayo Clinic Laboratories leverages clinical expertise, research integration, and advanced diagnostic capabilities, with demand across complex disease categories. Tempus AI differentiates itself through data-driven precision medicine platforms and AI-enabled analytics, combining molecular testing with large-scale clinical and genomic datasets to support oncology decision-making. Companies are pursuing service portfolio expansion through innovation in genomic profiling, liquid biopsy testing, and pharmacogenomic services. Strategic collaborations between diagnostic service providers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities. Service providers are investing in AI-enabled analytics and digital infrastructure to improve interpretation efficiency and scalability.

Short Conclusion

The molecular pathology services market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and expanding healthcare investment. The transition from specialized diagnostic niche to foundational component of modern healthcare delivery represents a fundamental shift in clinical decision-making. While challenges related to capital requirements, reimbursement variability, and regulatory complexity persist, strategic investments in technology, talent development, and clinical partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with molecular pathology services evolving into critical enablers of future clinical decision-making across oncology, rare diseases, infectious diseases, and pharmacogenomics.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Molecular Pathology Services Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Molecular Pathology Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Precision Medicine Landscape
• 3.8 Testing Volume Analysis
• 3.9 Patient Population Analysis by Major Disease Areas
• 3.10 Biomarker Testing Adoption Trends
• 3.11 Oncology Molecular Diagnostics Landscape
• 3.12 Companion Diagnostics Utilization Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Molecular Pathology Services
• 6.2 Product and Service Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis for Molecular Diagnostic Assays
• 6.5 Technology Roadmap
• 6.6 AI Integration in Molecular Pathology Workflows
• 6.7 Digital Pathology and Informatics Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Molecular Pathology Services Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology

9. Global Molecular Pathology Services Market Segment Analysis (2021-2035)

• 9.1 By Service Type
  • 9.1.1 Molecular Diagnostic Testing Services
  • 9.1.2 Companion Diagnostic Testing Services
  • 9.1.3 Genomic Profiling Services
  • 9.1.4 Biomarker Testing Services
  • 9.1.5 Infectious Disease Molecular Testing Services
  • 9.1.6 Pharmacogenomic Testing Services
• 9.2 By Technology
  • 9.2.1 Polymerase Chain Reaction (PCR)
  • 9.2.2 Quantitative PCR (qPCR)
  • 9.2.3 Digital PCR (dPCR)
  • 9.2.4 Next-Generation Sequencing (NGS)
  • 9.2.5 Fluorescence In Situ Hybridization (FISH)
  • 9.2.6 Microarray-Based Testing
  • 9.2.7 Sanger Sequencing
  • 9.2.8 Other Molecular Technologies
• 9.3 By Application
  • 9.3.1 Oncology
  • 9.3.2 Hematological Disorders
  • 9.3.3 Infectious Diseases
  • 9.3.4 Genetic and Rare Diseases
  • 9.3.5 Neurological Disorders
  • 9.3.6 Cardiovascular Disorders
  • 9.3.7 Other Applications
• 9.4 By Sample Type
  • 9.4.1 Tissue Samples
  • 9.4.2 Blood Samples
  • 9.4.3 Bone Marrow Samples
  • 9.4.4 Cytology Samples
  • 9.4.5 Other Sample Types
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Independent Diagnostic Laboratories
  • 9.5.3 Academic and Research Institutes
  • 9.5.4 Specialty Clinics
  • 9.5.5 Pharmaceutical and Biotechnology Companies

10. Global Molecular Pathology Services Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Molecular Pathology Services Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Quest Diagnostics
• 13.2 Labcorp
• 13.3 NeoGenomics Laboratories
• 13.4 Sonic Healthcare
• 13.5 Eurofins Scientific
• 13.6 ARUP Laboratories
• 13.7 Mayo Clinic Laboratories
• 13.8 Tempus AI
• 13.9 Foundation Medicine
• 13.10 Caris Life Sciences
• 13.11 Guardant Health
• 13.12 Exact Sciences
• 13.13 Natera
• 13.14 Fulgent Genetics
• 13.15 Unilabs

14. Global Molecular Pathology Services Market Commercial Forecast Analysis

• 14.1 Molecular Diagnostic Testing Services Forecast
• 14.2 Companion Diagnostic Testing Services Forecast
• 14.3 Genomic Profiling Services Forecast
• 14.4 Biomarker Testing Services Forecast
• 14.5 Infectious Disease Molecular Testing Services Forecast
• 14.6 Pharmacogenomic Testing Services Forecast
• 14.7 NGS-Based Testing Services Forecast
• 14.8 Liquid Biopsy Testing Services Forecast

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends